Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today ...

Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

Eli Lilly (LLY) on Tuesday launched higher doses of Zepbound, or tirzepatide, in single-dose vials and reduced the prices of two smaller doses of the weight-loss drug for self-pay patients. The ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Organovo Holdings Inc. (ONVO) on Wednesday reported a loss of $3.4 million in its fiscal third quarter. On a per-share basis, the San Diego-based company said it had ...

Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary ...

Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314.

SAN DIEGO (AP) — SAN DIEGO (AP) — Organovo Holdings Inc. (ONVO) on Wednesday reported a loss of $3.4 million in its fiscal third quarter. On a per-share basis, the San Diego-based company said ...